Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25955921 | 0.84 | NPC1 (0.37) | HAO1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL2829829 | 0.81 | EGFR (0.44) | EGFRKDRHAO1SMN1; SMN2CYP1A2 | |
| SCHEMBL25331492 | 0.78 | NPSR1 (0.36) | NPC1RAB9ASMN1; SMN2TSHRMAPT | |
| SCHEMBL2831891 | 0.73 | LIPE (0.35) | NPC1RAB9ASMN1; SMN2TSHRMAPT | |
| SCHEMBL2185810 | 0.73 | EGFR (0.43) | EGFRKDRHAO1MEN1KMT2A | |
| SCHEMBL3654965 | 0.72 | EGFR (0.45) | EGFRKDRHAO1SLC6A4 | |
| SCHEMBL21863802 | 0.70 | EGFR (0.43) | EGFRKDRSLC6A4 | |
| SCHEMBL31527918 | 0.69 | EGFR (0.45) | EGFRKDRSLC6A4FFAR4MAP4K4 | |
| SCHEMBL19510766 | 0.68 | ALDH1A1 (0.55) | NPC1RAB9ASMN1; SMN2TSHRMAPT | |
| SCHEMBL18575400 | 0.68 | KDR (0.44) | EGFRKDRHAO1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | ADDEX PHARMA, S.A. (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | ADDEX PHARMA, S.A. (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | ADDEX PHARMA, S.A. (CH) | 2013-06-13 | — | — | US | disclosed |
| EP-2134690-B1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2134690-B1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8299101-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators | Janssen Pharmaceuticals, Inc. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299101-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators | Janssen Pharmaceuticals, Inc. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299101-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators | Janssen Pharmaceuticals, Inc. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMECEUTICALS, INC (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMECEUTICALS, INC (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMECEUTICALS, INC (US) | 2010-04-22 | — | — | US | disclosed |
| EP-2134690-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008107480-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107480-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | GRM2, GRIK2, GRM1 | EGFR 1478/4885KDR 1879/4885HAO1 2887/4885 |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | GRM2, GRM1, GRM3 | EGFR 1401/4885KDR 1827/4885HAO1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.